(Q37933413)

25 August 2017

title

Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration (English)

1 reference

25 August 2017

1 reference

Issam Zineh

1

1 reference

25 August 2017

Michael A Pacanowski

series ordinal

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 August 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

31

1 reference

25 August 2017

issue

8

1 reference

25 August 2017

page(s)

729-735

1 reference

Pharmacogenetics of chronic cardiovascular drugs: applications and implications

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.8.729

Can the pharmaceutical industry reduce attrition rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.8.729

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.8.729

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.8.729

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.8.729

Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.8.729

21 January 2018

Identifiers

DOI

10.1592/PHCO.31.8.729

1 reference

25 August 2017

1 reference